2025-10-01 - Analysis Report
Okay, here's an analysis of TEM (Unknown Company) based on the data you provided, formatted as requested.

## TEM (Unknown Company) Analysis

**Overview:** Tempus AI (TEM) is a company focused on precision oncology, leveraging data and technology to personalize healthcare.

### 1. Performance vs. S&P 500 (VOO)

*   **Cumulative Return:**
    *   TEM: 29.57%
    *   VOO: 26.79%
*   **Outperformance:** TEM has outperformed VOO by 2.78% in cumulative return.
*   **Relative Divergence:** The relative divergence is currently at 36.9, which means TEM's current performance is positioned in the 36.9th percentile of its historical divergence range compared to VOO.
*   **Key Metrics Table:**

| Metric | Value   |
| :------- | :------- |
| Alpha   | 4.0%   |
| Beta    | 0.3    |
| CAGR    | 30.0%   |
| MDD     | 70.1%  |
| Cap(B)    | 13.7  |

**Analysis:**  TEM has outperformed the S&P 500 (VOO) over the period examined, with a positive alpha.  The beta of 0.3 indicates that TEM's price is not very sensitive to the movement of the S&P 500. However, its MDD (Maximum Drawdown) is substantial, suggesting high volatility and risk. The CAGR is a reasonable number, and TEM has a relatively high cap.

### 2. Recent Price Action

*   **Current Price:** 79.34
*   **Last Market Data:**
    *   Price: 78.975
    *   Previous Close: 78.57
    *   Change: 0.52
*   **Moving Averages:**
    *   5-day MA: 79.085
    *   20-day MA: 82.0845
    *   60-day MA: 70.322

**Analysis:** The current price is below the 20-day moving average, suggesting a short-term downtrend or consolidation. However, it is above the 60-day moving average, indicating a longer-term uptrend. The recent small price increase of 0.52 suggests a minor upward movement.

### 3. Market Risk Indicators

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 47.57
*   **PPO:** -1.84
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (13 shares - Very Safe - MRI:0.90) Monthly invest 5.9% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-09-02)
*   **Delta_Previous_Relative_Divergence (20-day):** -13.5 (Negative - Short-term decline)
*   **Expected Return:** NaN (Not Available)

**Analysis:** The MRI of 0.9 suggests a "High Investment Recommended" based on the model. The RSI of 47.57 is neutral. The PPO being negative indicates that the short-term moving average is below the long-term moving average, suggesting a potential downtrend or weakening momentum. The negative change in relative divergence (-13.5) confirms a recent short-term decline relative to the S&P 500. The "Hybrid Signal" recommends a 100% investment of available cash, potentially indicating a bullish outlook. Due to the large "change" value of 0.52, it is possible the stock experienced a rapid surge as of the last market day recorded.

### 4. Recent News & Analyst Opinions

*   **Recent News Highlights:**
    *   Valuation Assessment: Investor interest is growing, but clear catalysts are needed.
    *   Comparison with ILMN: Analysis of TEM vs. ILMN in the precision oncology space.
    *   FDA Clearance: Recent FDA clearances boosting the growth outlook.
    *   Stock Pullback: A pullback from a recent high after FDA clearance.
*   **Analyst Consensus:**
    *   Overall: Buy
    *   Mean Rating: 2.15 (~Buy)
    *   Number of Opinions: 11
    *   Target Price: Avg: 74.82 / High: 98.00 / Low: 60.00
    *   Recent Rating Changes: No changes are recorded in the provided data.

**Analysis:** Recent news is generally positive, focusing on FDA clearances and potential growth drivers. The analyst consensus is "Buy," but the average target price (74.82) is below the current price (79.34), implying a potential overvaluation or limited upside according to analysts.  The wide range in target prices (60.00 to 98.00) suggests differing opinions on the stock's future potential.

### 5. Recent Earnings Analysis

| Date       | EPS   | Expected EPS |
| :--------- | :------ | :------------- |
| 2025-08-08 | -0.22 | -0.22988       |
| 2025-05-06 | -0.24 | -0.26003       |
| 2025-02-24 | -0.18 | -0.15          |
| 2024-11-04 | -0.25 | -0.26608       |
| 2024-08-06 | -0.63 | -0.59          |

**Analysis:** TEM has consistently reported negative EPS for the past several quarters. In most instances, the reported EPS was better than expected (beat expectation), except for 2025-02-24, where the EPS missed the expectation.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
| :--------- | :------- | :-------------- |
| 2025-06-30 | $0.31B | 61.99%          |
| 2025-03-31 | $0.26B | 60.69%          |
| 2024-12-31 | $0.20B | 60.83%          |
| 2024-09-30 | $0.18B | 58.50%          |
| 2024-06-30 | $0.17B | 45.50%          |

**Capital and Profitability:**

| Quarter    | Equity  | ROE        |
| :--------- | :-------- | :----------- |
| 2025-06-30 | $0.31B  | -13.84%    |
| 2025-03-31 | $0.33B  | -20.86%    |
| 2024-12-31 | $0.06B  | -23.10%    |
| 2024-09-30 | $0.05B  | -141.16%   |
| 2024-06-30 | $0.10B  | -562.04%   |

**Analysis:** Revenue has been consistently increasing over the past five quarters, indicating growth. Profit margins are relatively high, suggesting strong pricing power or efficient cost management, though profitability margin had a noticeable spike between 2024-06-30 and 2024-09-30 and has since gradually decreased. However, the Return on Equity (ROE) is significantly negative, indicating that the company is not generating profits from its equity.

### 7. Summary and Conclusion

TEM demonstrates a mixed picture. It has outperformed the S&P 500 and enjoys positive news flow related to FDA clearances. The company is experiencing strong revenue growth and high profit margins. However, the negative EPS and ROE raise concerns about overall profitability. The high MDD suggests that while TEM has the potential for significant returns, it comes with substantial risk.

While analyst consensus leans towards a "Buy," the average target price is below the current market price, suggesting cautious optimism or potential overvaluation. Investors should carefully consider their risk tolerance and conduct further due diligence before investing in TEM. The growth potential in precision oncology and recent FDA clearances are promising signs, but the lack of current profitability warrants careful consideration.

